Patents Assigned to C4 Therapeutics, Inc.
-
Publication number: 20230095223Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: November 11, 2021Publication date: March 30, 2023Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
-
Publication number: 20230082430Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.Type: ApplicationFiled: April 18, 2022Publication date: March 16, 2023Applicant: C4 Therapeutics, Inc.Inventors: James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips
-
Publication number: 20230060334Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: September 1, 2022Publication date: March 2, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
-
Patent number: 11584748Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.Type: GrantFiled: October 16, 2020Date of Patent: February 21, 2023Assignee: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
-
Publication number: 20230014124Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: February 1, 2021Publication date: January 19, 2023Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
-
Publication number: 20230019060Abstract: The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.Type: ApplicationFiled: September 2, 2021Publication date: January 19, 2023Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Roger Norcross, Fabian Dey, Annick Goergler, Eric Kusznir
-
Patent number: 11524949Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.Type: GrantFiled: May 14, 2020Date of Patent: December 13, 2022Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
-
Publication number: 20220372016Abstract: This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.Type: ApplicationFiled: June 18, 2021Publication date: November 24, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Katrina L. Jackson, Minsheng He, Yanke Liang, Mark E. Fitzgerald, Victoria Garza
-
Publication number: 20220313827Abstract: This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: December 14, 2020Publication date: October 6, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Chi-li Chen, Martin Duplessis, Minsheng He, Kiel Lazarski
-
Publication number: 20220313826Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: November 30, 2020Publication date: October 6, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Patent number: 11459335Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: December 19, 2019Date of Patent: October 4, 2022Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
-
Publication number: 20220289738Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: ApplicationFiled: January 14, 2022Publication date: September 15, 2022Applicant: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
-
Publication number: 20220251061Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.Type: ApplicationFiled: May 14, 2020Publication date: August 11, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
-
Patent number: 11407732Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.Type: GrantFiled: October 11, 2021Date of Patent: August 9, 2022Assignee: C4 Therapeutics, Inc.Inventors: James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips
-
Patent number: 11401256Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: GrantFiled: March 4, 2020Date of Patent: August 2, 2022Assignee: C4 Therapeutics, Inc.Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
-
Publication number: 20220098194Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.Type: ApplicationFiled: December 2, 2021Publication date: March 31, 2022Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakin, Jeremy L. Yap
-
Patent number: 11254672Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.Type: GrantFiled: March 4, 2020Date of Patent: February 22, 2022Assignee: C4 Therapeutics, Inc.Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
-
Patent number: 11185592Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: May 22, 2020Date of Patent: November 30, 2021Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
-
Publication number: 20210198256Abstract: Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.Type: ApplicationFiled: March 4, 2021Publication date: July 1, 2021Applicant: C4 Therapeutics, Inc.Inventors: Christopher G. Nasveschuk, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap, Rhamy Zeid
-
Publication number: 20210106688Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: May 22, 2020Publication date: April 15, 2021Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael